Description
BridgeBio Pharma’s $253 Million Attruby Boom — Can Three New Drug Launches Supercharge Growth?
BridgeBio Pharma, Inc. reported continued commercial growth alongside advancing pipeline developments in its recent quarter. The company’s ATTR cardiomyopathy franchise, led by Attruby (acoramidis), achieved $253.2 million in U.S. net product revenue, reflecting a 14% sequential increase and a 134% year-over-year rise. Attruby’s growth is primarily driven by first-line patient starts, supported by emerging real-world evidence demonstrating superior clinical outcomes compared to competitor tafamidis. Two independent real-world data analyses showed reductions in clinical worsening, hospitalizations, and other morbidity measures, reinforcing Attruby’s positioning as a near-complete transthyretin stabilizer, which remains critical in the market. However, a large proportion of potential prescribing physicians remain untapped, representing both a growth opportunity and a commercial challenge as competitors also target this physician segment. The company highlighted additional pipeline milestones with three upcoming potential product launches in the next seven months.



